ZBIO today
$28.23-$0.47 (-1.66%)close Nov 12, 2026Trend
DailyUptrend (starting)
4 hourStrong Bearish
1 hourAscending Triangle
15 minLeaning Bullish
5 minSymmetric Triangle
Daily trend turns down below $8.28
Key levels
Resistance$30.85
Resistance$28.83
Support$26.66
Support$24.08
Latest news & SEC filings
NewsZenas BioPharma to take part in Jefferies healthcare event in London
EarningsZenas BioPharma Posts Q3 2026 Results
All ZBIO news →About Zenas BioPharma
Zenas BioPharma is a clinical-stage biopharmaceutical company developing immunology-based therapies for autoimmune diseases. Its lead candidate, obexelimab, is an antibody designed to inhibit B cells without depleting them, and is being studied in IgG4-related disease, relapsing multiple sclerosis, and systemic lupus erythematosus. The company also develops orelabrutinib for progressive multiple sclerosis and earlier-stage programs for other inflammatory conditions. It operates globally, with partners in China and other regions.
Based on the company's 10-K filed Mar 16, 2026.
Nasdaq · Healthcare
Zenas BioPharma, Inc. (ZBIO)
What Is the Price Target for ZBIO?
SEPT Low Target
$32.00
SEPT Mid Target
$44.00
SEPT High Target
$48.00
Analyst Consensus
$44.00
Is ZBIO a Buy or Sell Right Now?
Thesis
- •Revenue growing 100.0% YoY with ACCELERATING trend — accelerating momentum.
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ZBIO.
Start Free Trial →Is ZBIO Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
P/B, Analyst Consensus
Fair Value
$35.56
22
Moat Score
NONE
2/9
Piotroski Score
0.2
Altman Z-Score
What Is Smart Money Doing with ZBIO?
Insider Signal
BUYING
12 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| MOULDER LEON O JR | director officer | Buy | 60,000 | $1.0M | May 18, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ZBIO Growth Story
Revenue YoY
100.0%
3yr Revenue CAGR
N/A%
EPS Growth YoY
29.02%
FCF Growth YoY
-43.9%
Revenue Trend
ACCELERATING
Dark Pool Trades for ZBIO
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ZBIO, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 17:57:05 | $28.26 | 105,700 | $$3.0M | BUY |
| 17:51:23 | $28.25 | 105,700 | $$3.0M | BUY |
| 16:21:22 | $28.70 | 1,400 | $$40K | BUY |
| 16:20:07 | $28.62 | 1,100 | $$31K | BUY |
| 16:20:03 | $28.71 | 2,800 | $$80K | BUY |
5 dark pool trades shown · $$6.1M preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Zenas BioPharma, Inc. (ZBIO) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ZBIO — frequently asked questions
What is ZBIO stock price today?
Zenas BioPharma, Inc. (ZBIO) is at $28.23, down 1.66% (-$0.47) at the Nov 12, 2026 close.
Why is ZBIO stock moving today?
Latest ZBIO news — Nov 9, 2026: Zenas BioPharma to take part in Jefferies healthcare event in London · Nov 5, 2026: Zenas BioPharma Posts Q3 2026 Results
What is the ZBIO price target?
The average analyst price target for ZBIO is $44.00, ranging from $32 to $48, based on 3 analysts.
What do analysts rate ZBIO?
Analyst ratings for ZBIO: 0 Buy, 9 Hold, 0 Sell — consensus Hold.
Did ZBIO beat earnings?
ZBIO last reported on Aug 13, 2026: EPS -$1.77 vs -$1.12 expected — a miss of 58.0%.
Does ZBIO pay a dividend?
ZBIO does not currently pay a dividend.
What are ZBIO support and resistance levels?
Support: $26.66, $24.08, $20.60. Resistance: $28.83, $30.85, $33.25.
What are insiders doing with ZBIO?
Insider activity: BUYING, 12 buys and 0 sells in the last 90 days.
What is the latest news on ZBIO?
Nov 9, 2026: Zenas BioPharma to take part in Jefferies healthcare event in London · Nov 5, 2026: Zenas BioPharma Posts Q3 2026 Results